What are the critical protein expression changes and post-translational modifications (phosphorylation, ubiquitination, glycosylation) at the aging synapse that drive early Alzheimer disease pathophysiology? Focus on: (1) synaptic vesicle proteins and their PTM states, (2) scaffold proteins and their altered interactions, (3) receptor tyrosine kinase signaling cascades, (4) mitochondrial proteins at the synapse, and (5) proteins involved in amyloid precursor protein processing. How do these proteomic changes correlate with cognitive decline and which represent therapeutic intervention points?
Synaptic activity-dependent phosphorylation of synapsin-1 by CamKII and calcineurin dynamically regulates vesicle mobilization, while Cdk5-mediated phosphorylation of synaptophysin and SV2A facilitates interaction with APP in presynaptic terminals, creating a hub where impaired neurotransmitter release converges with local Aβ secretion.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Synaptic Activity Calcium Influx at Active Zone"]
B["CamKII Activation Synapsin-1 SYN1 Phosphorylation"]
C["SYN1 Dissociates from Reserve Pool Vesicle Mobilization"]
D["Calcineurin Dephosphorylation Feedback Vesicle Reclustering"]
E["Cdk5 Aberrant Activation SYN1 SV2A Synaptophysin Phosphorylation"]
F["Release Probability Reprogrammed Short-Term Plasticity Disrupted"]
G["APP Processing Modulated Secretase Access Altered by Vesicle State"]
H["Synaptic Dysfunction AD ALS Co-pathology"]
A --> B
B --> C
C --> D
D --> B
E --> F
F --> G
E --> H
G --> H
style E fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID6 mediumValidation: 0%5 supporting / 1 opposing
✓For(5)
5
1
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
1
MECH 5CLIN 0GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Autophagy and apoptosis dysfunction in neurodegene…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Synaptic Proteomic Changes in Early Alzheimer Disease Pathophysiology
Title: PSD-95 S561 Phosphorylation Links Synaptic Failure to APP Processing
Mechanism: Age-dependent activation of cyclin-dependent kinase 5 (Cdk5), likely through calpain-mediated p35 cleavage to p25, leads to pathological phosphorylation of PSD-95 at serine 561. This modification disrupts PSD-95's PDZ domain interactions with AMPA receptor subunits (GRIA1-4) and NMDA
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic's Evaluation: Synaptic Proteomic Hypothesis in Early Alzheimer Disease
Overall Framing Assessment
Before evaluating individual hypotheses, a structural concern must be raised: the research question proposes five distinct proteomic domains, but only one mechanistic hypothesis is presented. This evaluation must assess what exists. The remaining domains—synaptic vesicle proteins, scaffold interactions, RTK signaling, mitochondrial proteins, and APP processing—lack corresponding hypotheses, making the request internally inconsistent. I'll evaluate what is provided and flag wh
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Evaluation: Synaptic Proteomic Hypotheses in Early Alzheimer Disease
Executive Summary
The research question addresses a critical and underexplored frontier in Alzheimer's disease (AD) pathophysiology: the proteomic architecture of the aging synapse as a proximal driver of early AD neurodegeneration. I will evaluate the presented hypothesis, construct interpretable frameworks for the four missing domains, identify the highest-translational opportunities, address the Skeptic's mechanistically sound critique, and propose an underappreciated mechanism worthy of investigatio
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF we pharmacologically inhibit Cdk5 activity (using roscovitine) in primary hippocampal neurons AND simultaneously measure synaptic vesicle release probability (via FM4-64 destaining assays) and extracellular Aβ42 levels (via ELISA), THEN neurons will exhibit significantly reduced Aβ42 secretion (≥40% decrease) without proportional change in release probability compared to vehicle controls within 4 hours using cultured hippocampal neurons.
pendingconf: 0.75
Expected outcome: Cdk5 inhibition will reduce extracellular Aβ42 concentration by ≥40% while release probability remains within ±15% of baseline, demonstrating dissociable effects on APP processing versus vesicle dynamics.
Falsified by: If Cdk5 inhibition produces equivalent changes in both release probability AND Aβ secretion (i.e., both change by >30% in the same direction), this would indicate these processes are not independently regulated by Cdk5 phosphorylation as proposed. Alternatively, if Aβ42 levels remain unchanged despite robust Cdk5 inhibition (verified by Western blot for phospho-tau), the Cdk5-APP interaction mechanism is falsified.
Method: Primary hippocampal neurons from E18 rats will be cultured for 14-21 days. Cdk5 will be inhibited using 50μM roscovitine or equivalent. Release probability will be assessed via optical measurement of FM4-64 destaining kinetics at single boutons during 10Hz stimulation. Aβ42 will be measured by ELISA from matched culture media samples. Phosphorylation status will be verified by immunoblot for phospho-synaptophysin and phospho-SV2A.
IF we express synapsin-1 S9A phospho-mutant (non-phosphorylatable) in synapsin-1/2 double knockout neurons via viral transduction AND compare to wild-type synapsin-1 rescue, THEN the phospho-mutant will demonstrate both reduced synaptic vesicle mobilization during prolonged stimulation AND decreased co-immunoprecipitation of synaptophysin with APP compared to wild-type rescue within 5-7 days post-infection using primary neuron cultures.
pendingconf: 0.68
Expected outcome: S9A-expressing neurons will show ≥50% reduction in synaptic vesicle mobilization (measured as refractory pool replenishment rate) and ≥40% reduction in synaptophysin-APP co-immunoprecipitation compared to wild-type synapsin-1 rescue controls.
Falsified by: If the S9A mutant shows normal vesicle mobilization but still demonstrates reduced APP interaction, this would indicate synapsin-1 phosphorylation regulates APP processing independently of vesicle dynamics, contradicting the 'hub' hypothesis. Conversely, if APP interaction is preserved but mobilization is impaired, this would indicate separate pathways. If neither parameter differs significantly from wild-type, the synapsin-1 phosphorylation mechanism is falsified.
Method: Synapsin-1/2 DKO neurons will be infected with AAV vectors expressing GFP-tagged human synapsin-1 (WT or S9A). After 5-7 days expression, vesicle mobilization will be measured via total internal reflection fluorescence (TIRF) microscopy of synaptobrevin-pHluorin during 40 Hz stimulation trains. Co-immunoprecipitation will use anti-APP antibodies followed by immunoblot for synaptophysin and synapsin-1. Phosphorylation status will be confirmed by Phos-tag SDS-PAGE.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
SYN1 — Search for structure
Click to search RCSB PDB